Navigation Links
OncoGenex Pharmaceuticals to Present at RBC Capital Markets' Healthcare Conference
Date:3/1/2010

account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='85801917';s.tl(this,'o','ExternalLink');" target='_blank' href="http://ir.oncogenex.com">http://ir.oncogenex.com. A webcast replay will be available approximately two hours after the call and will be archived for 30 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, OGX-011. The companies expect to initiate two Phase 3 trials in castrate resistant prostate cancer in 2010, and a third Phase 3 trial in non-small cell lung cancer in early 2011; OGX-427 is in Phase 1 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

More information about OncoGenex is available at

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
2. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
3. OncoGenex Reports Third Quarter 2009 Financial Results
4. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
5. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
6. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
7. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
8. OncoGenex Reports Second Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
11. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... York , August 1, 2014 ... Transparency Market Research "Biophotonics Market - Global Industry Analysis, ... the market was valued at USD 25.16 billion in ... by 2020, growing at a CAGR of 10.4% from ... Market Report at  http://www.transparencymarketresearch.com/biophotonics-market.html Increasing demand ...
(Date:8/1/2014)... August 01, 2014 BCC Research ( ... DRUG DELIVERY: TECHNOLOGIES AND GLOBAL MARKETS , that the ... expected to grow to nearly $38.8 billion by 2018, ... 27.2%. The aptamer delivery category, the fastest moving segment ... CAGR. , The field of RNAi therapeutics has shown ...
(Date:8/1/2014)... Testing the mechanical properties of ... understanding embryonic development. How and why embryonic ... functionally distinct tissues is important because abnormalities can ... McDevitt, Melissa Kinney, and Rabbia Saeed worked from ... cues to control many aspects of embryo development. ...
(Date:7/31/2014)... Today BioSpace , the leading life sciences employment and news website, ... sciences community in Illinois , Indiana ... Michigan , Minnesota , Missouri ... and Wisconsin . BioMidwest is a leader ... on BioSpace originating in this region in 2013. The life sciences sector ...
Breaking Biology Technology:Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Study Links Biomechanics and Gene Expression in Stem Cells 2Midwest Biotech Leaders Featured On BioSpace Map 2
... ... ... ... ...
... ... ... ... ...
... , ... ... ... ...
Cached Biology Technology:Stem Cell Innovations to Provide Research and Assay Services to Agennix. 2Stem Cell Innovations to Provide Research and Assay Services to Agennix. 3Stem Cell Innovations to Provide Research and Assay Services to Agennix. 4Stem Cell Innovations to Provide Research and Assay Services to Agennix. 5InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 2InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 3InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 4InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 5InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 6InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 7Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 2Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 3Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 4Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 5Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 6Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 7Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 8Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 9Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 10Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 11
(Date:7/31/2014)... twin pairs have identified a gene mutation that may allow ... of sleep per night. The genetic variant also appears ... , Results show that a participant with p.Tyr362His a ... sleep duration of only five hours, which was more than ... about six hours and five minutes per night. The ...
(Date:7/31/2014)... team of scientists from Spain, France, and the ... that is the oldest definitive member of the ... amber. The discovery and description were made possible ... synchrotron imaging technique, which allows the detailed study ... new species is described in the journal ...
(Date:7/31/2014)... Prolonged exposure to loud noise alters how the ... distinguishing speech sounds, according to neuroscientists at The ... paper published this week in Ear and ... how noise-induced hearing loss affects the brain,s recognition ... reaches all corners of the population, affecting an ...
Breaking Biology News(10 mins):Study of twins discovers gene mutation linked to short sleep duration 2UT Dallas study reveals effect of loud noises on brain 2
... virologists headed by Professor Hans-Georg Kräusslich at Heidelberg ... of Applied Tumor Virology of the Deutsches Krebsforschungszentrum ... first to label Human Immunodeficiency Viruses (HIV) for ... the virus. , The labeling permits scientists to ...
... headed by Professor Hans-Georg Kräusslich at Heidelberg University ... Applied Tumor Virology of the Deutsches Krebsforschungszentrum (German ... to label Human Immunodeficiency Viruses (HIV) for visual ... virus. , The labeling permits scientists to observe ...
... to learn from bad bugs, according to Gilbert Waldbauer, whose ... was published March 1 (Prometheus Books). , "We know a ... their research," said Waldbauer, professor emeritus of entomology at the ... of insects, a mere 2 percent are considered pests. Just ...
Cached Biology News:New Species of Coral Discovered Off Southern California 2Virologists make major step towards understanding the process of HIV infection 2Bugs, even 'bad' ones, can be educationally beneficial, new book says 2Bugs, even 'bad' ones, can be educationally beneficial, new book says 3
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
... without ammonium sulfate are compatible with thermostable ... Taq and AmpliThem™™ DNA polymerases. You can ... in one experiment by adding your own ... PreMixes supplied with the kit. This capability ...
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
... agent for removing RNase from ... pipettors. It is also ... from microcentrifuge tubes without inhibiting ... (R) is a ...
Biology Products: